Search
for
Sort by
Research 451–480 of 1000+
- A Patient Preference-Weighted Quantitative Benefit-Risk Analysis of Ritlecitinib for Alopecia Areata to Inform Medical Decision Making
- Poster Presentations at the 28th Joint Meeting of the International Society of Dermatopathology, March 5–6, 2025, Orlando, Florida, USA
- Polynucleotides Versus Platelet-Rich Plasma for Androgenetic Alopecia: A Case Series
- Actualización de la tricodinia, un reto para los dermatólogos
- Erythrodermic Psoriasis in the Context of Emerging Triggers: Insights into Dupilumab-Associated and COVID-19-Induced Psoriatic Disease
- Comprehensive Safety Exposure‐Response Analysis to Support Ritlecitinib Dose Selection
- Comprehensive Review on Hair Loss and Restorative Techniques: Advances in Diagnostic, Artistry, and Surgical Innovation
- Alopecia Areata: Understanding the Pathophysiology and Advancements in Treatment Modalities
- Telitacicept for systemic lupus erythematosus with post‑surgical papillary thyroid carcinoma: A case report
- Real-life effectiveness and safety of baricitinib in 17 Japanese patients with alopecia areata: a 60-week single center study
- Diagnostic Signs and Symptoms of Cyanocobalamin Deficiency at Rural Setting in India: Novel Method of Supplementation
- Anifrolumab treatment improves patient-reported quality of life and decreases disease activity and corticosteroid use in patients with systemic lupus erythematosus: A qualitative study in Denmark
- Pharmacotherapy for Keloids and Hypertrophic Scars
- Comparative efficacy and safety of JAK inhibitors in the treatment of moderate-to-severe alopecia areata: a systematic review and network meta-analysis
- Light exposure and its applications in human health
- Long‐term efficacy and safety of baricitinib in patients with severe alopecia areata: 104‐week results from BRAVE‐AA1 and BRAVE‐AA2
- Erosive pustular dermatosis of the scalp: A case report
- Screening for latent infectious disease in patients with alopecia areata before initiating JAK inhibitors therapy: a single-center real-world retrospective study
- The development of oral hairy leukoplakia during JAK inhibitor baricitinib therapy
- Hair disorders associated with post-COVID-19 infection in females: a cross-sectional study
- Tinea capitis caused by Trichophyton violaceum in an immunocompetent elderly patient: a case report and review of literature
- Dermatoses in Postmenopausal Women in a Tertiary Health Care Center of Bihar: A Prospective Cross-Sectional Study
- Recent Advances in Understanding of the Etiopathogenesis, Diagnosis, and Management of Hair Loss Diseases
- Analysis of Prescribing Practices in the Dermatology Outpatient Department of a Tertiary Care Teaching Hospital
- Neuropathic Pruritus: An Underrecognized and Often Misdiagnosed and Difficult to Treat Medical Condition
- An ancestral recipe of “Champigny Saumure” to be used tepid by topical way could be useful to combat Patton-Lynch’s Erosive pustular dermatosis of the scalp
- Ayurvedic Rasayan formulations having potential for managing post COVID ailments- a narrative review
- Which is the ideal JAK inhibitor for alopecia areata – Baricitinib, tofacitinib, ritlecitinib or ifidancitinib - Revisiting the immunomechanisms of the JAK pathway
- Impact of the COVID-19 Pandemic on Tertiarycare University Dermatology Outpatient Clinic and Dermatology Procedures
- Peer Review Report For: Pattern changes of cutaneous dermatoses among Iraqi women preceding and during the COVID-19 pandemic [version 3; peer review: 2 approved]